GlassScriptPhysician profile
Anurag Gupta
NPI 1144285552
$5,220.29
in general payments reported to CMS, 2019-2025
33 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $427 · 2021: $434 · 2022: $740 · 2023: $329 · 2024: $1,196 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $631.13 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Acadia Pharmaceuticals INC | $468.23 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $451.91 | 2019-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $433.60 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $432.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $368.48 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.79 | 2020-2025 | Caplyta |
| Almatica Pharma LLC | $281.31 | 2022-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $260.51 | 2019-2025 | Fanapt |
| Alkermes, INC. | $198.23 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $183.71 | 2019-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $171.09 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $149.05 | 2021-2025 | Ingrezza |
| Bausch Health US, LLC | $138.45 | 2022-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $105.49 | 2022-2025 | Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $83.01 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $71.18 | 2023-2024 | Azstarys |
| Allergan, INC. | $71.02 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $61.62 | 2021-2022 | |
| Eisai INC. | $55.30 | 2020-2022 | |
| Adlon Therapeutics L.P. | $38.44 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $36.51 | 2022-2025 | Qelbree |
| Owp Pharmaceuticals, INC. | $35.08 | 2020-2025 | Subvenite |
| Abbott Laboratories | $24.30 | 2024 | Gallant |
| Sage Therapeutics, LLC | $23.99 | 2025 | Zurzuvae |
| Arbor Pharmaceuticals, INC. | $22.61 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $20.76 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $19.90 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $19.85 | 2022 | |
| Neos Therapeutics, LP | $13.90 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.04 | 2019 | |
| Shire North American Group INC | $11.69 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anurag Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.